Approximately 1% of the world’s population, namely around 71 million people globally are chronically infected with hepatitis C virus (HCV), which remains a leading cause of chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma on a worldwide basis [1–3].

In 2014, it was estimated that, in Europe, there was a population amounting to 19 million of HCV infected people but this estimate should be corrected based on the limited availability of data from certain areas notably including central and eastern countries [4]. On these grounds, HCV is deemed to be responsible for causing more than 86,000 deaths and 1.2 million disability-adjusted life years (DALYs) in the World Health Organization (WHO) European region and the cause of approximately one in four liver transplants performed in Europe in 2004 [5]. Taken together, these figures are directly and indirectly responsible for a substantial economic burden in Europe comparable to that of the Asia Pacific region and the Americas [6].

In 2016, the WHO set a goal to eliminate HCV as a major public health threat by 2030 through the diagnosis of 90% of individuals with HCV and initiating treatment in 80% of those eligible patients [1]. Collectively, these achievements would predictably reduce HCV-related mortality by 65%. Highly effective strategies spanning from prevention to treatment could render these aims accessible. For example, direct-acting antivirals (DAAs), first available in 2014, compared to previously employed interferon (IFN)-based regimens, offer the added values of oral administration, and have reduced duration of treatment, improved tolerability and sustained virologic response rates > 95% [7]. Nevertheless, so complex and stratified are barriers hampering HCV elimination, that only some European nations (France, Germany, Italy, Spain, Sweden, Switzerland, and the United Kingdom) are on track for meeting the WHO elimination targets by 2030, while others (Austria, Malta and the Netherlands) could only reach these goals by 2040 through expanded screening efforts [8].

With specific reference to recent studies, here I aim at delivering a perspective overview of barriers hampering HCV elimination and how these obstacles can be overcome in Europe.

In the pre-SARS-COV-2 era, Mendizabal et al. [9] classified barriers impeding HCV elimination into three different layers: i.e. patient-related; owing to providers; and structural. However, the SARS-CoV-2 epidemic has revolutionized research and practice priorities in the hepatological arena [10]. Accordingly, the stratified complexities that prevent achieving HCV elimination have now become more numerous and difficult to overcome. For example, even before the coronavirus disease 2019 (COVID-19), many countries were already lagging behind to ‘catch-up’ to elimination targets and, based on a Markov HCV disease burden modeling, a 1-year delay in HCV programs would expectedly result in excess morbidity and mortality owing to HCV infection [11].

With regard to the so-called “macro-elimination” area, the high proportion of undiagnosed and/or unlinked to care patients represents a major challenge. It has recently been estimated that this population at the F0–F3 liver fibrosis stage consists of at least 280,000 individuals [12]. Additionally, “micro-elimination” strategies include targeting populations belonging to a well-defined context (e.g., prison and dialysis unit); specific clinical features [e.g., people living with human immunodeficiency virus (HIV) and people living with blood disorders]; or a given geographic setting (e.g., town/province/nation) [13].

Several approaches may be implemented to target those obstacles that prevent effective elimination of HCV infection.

The present perspective article has identified some critical steps that need to be taken in order to achieve the goal to eliminate HCV as a major public health threat by 2030 in Europe. To this end, I have first briefly examined the epidemiological burden of HCV infection. Second, I have re-classified barriers which prevent the WHO-supported aim to eliminate HCV infection by year 2030. As regards patient-related barriers, I have discussed high-hazard cohorts including migrants, PWID and late presenters. These populations deserve special attention for screening and treatment purposes. Next, I have addressed those structural barriers that obstacle the WHO campaign: these include differences between the autonomous health-care systems and limits in national health care system pledges to eliminating HCV in Europe. Finally, in discussing how these barriers may be overcome, emphasis has been put on innovative diagnostic and therapeutic protocols of HCV infection; as well as on how health care providers and policy makers may improve organization aimed at delivering more efficient cures to eliminate HCV infection (Figure 1). Based on the sum of the above notions, I conclude, with Louis Pasteur, “it is within the power of man to eradicate infection from the earth [30]”.